Price setting and regulation in health services / Sarah L. Barber, Luca Lorenzoni, Tomáš Roubal.
(Health Financing Policy Brief, No. 7)
ISBN 978-92-4-000498-6

© Copyright World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/ 3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.


Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

The named authors alone are responsible for the views expressed in this publication.

Printed in Switzerland.
TABLE OF CONTENTS

Key messages .................................................................................. 4
Acknowledgments ........................................................................... 4
1. What constitutes price setting and regulation for health services? ............... 5
2. Why is price setting for health services important in the context of UHC? ........ 6
3. How does price setting and regulation fit within health financing policy? ....... 7
4. What do we know about price setting and regulation for health services from theory and practice? ................................................................. 9
   4.1. Individual negotiations .................................................................. 9
   4.2. Collective negotiations .................................................................. 10
   4.3. Unilateral price setting .................................................................. 10
   4.4. Price adjustments and add on payments to incorporate providers’ exogenous differences in costs ................................................................. 13
   4.5. Cost based pricing ....................................................................... 15
   4.6. Balance billing and financial protection ......................................... 16
   4.7. Using price levels to control for volumes and aim for budget neutrality ................................................................. 16
   4.8. Institutional entities for price setting and regulation ......................... 17
5. WHO’s perspective ....................................................................... 18
References ..................................................................................... 19
Key Messages

- With the increasing levels of public funding to health care, countries are taking strategic approaches in defining what services are purchased and paid for, and how to link payments with quality and performance.

- The price for health services is the amount that must be paid to elicit the supply and quality of health care services that society wishes to have and is willing to pay for.

- The process or negotiation by which prices are determined can be grouped into three main methods: individual negotiations between providers and purchasers, collective negotiation between associations of providers and purchasers, and unilateral decisions by purchasers.

- Collective and unilateral price setting eliminate price discrimination and have performed better in controlling the growth in health care costs. Both have the potential to improve quality better than individual negotiations. A single or collective purchaser also has the power to put some discipline into prices.

- Price adjustments are typically made to ensure coverage and access, for example, to health care providers in rural and remote areas; those treating disproportionately high numbers of low-income or high-cost patients to ensure coverage and quality; and facilities providing medical education.

- Countries have eliminated balance billing as a means of financial protection, in which providers are not permitted to charge patients more than the prices established for covered services.

- Building institutional capacity for price setting and regulation can support the use of prices as policy instruments to attain broader health-related objectives, i.e., guarantee coverage and financial protection, enhance quality and access, and increase efficiency.

ACKNOWLEDGMENTS

Information in this brief relies on a previous WHO/OECD publication by Barber, Lorenzoni, and Ong (2019a, 2019b). In preparing the earlier publication, substantive technical input and detailed annexes were prepared by Jane Hall, Maryam Naghsh Nejad, Kees Van Gool, Michael Woods, Sue Nowak, Alberto Marino, Zeynep Or, Coralie Gandré, Jonas Schreyögg, Ricarda Milstein, Naoki Ikekami, Chiu Wan Ng, Soonman Kwon, Viroj Tangcharoensathien, Walaiporn Patcharanarumol, Taweesri Greetong, Waraporn Suwanwela, Nantawan Kesthom, Shaheda Viriyathorn, Nattadhanai Rajatanavin, Woranan Witthayapipopsakul, Jain Nishant. From WHO, we thank Peter Cowley, Jon Cylus, Tamas Evetovits, Paul Ong, Liviu Vedrasco, Lluis Vinyals Torres. Inke Mathauer and Joe Kutzin provided valuable comments on this brief. The authors remain responsible for errors and omissions.

We gratefully acknowledge financial support from the Kobe Group, Japan.
1. WHAT CONSTITUTES PRICE SETTING AND REGULATION FOR HEALTH SERVICES?

The purpose of this brief is to explain health services price setting and regulation in the context of accelerating progress towards universal health coverage (UHC). There is a special focus on the implications for middle-income settings, where increases in public spending have been accompanied by new ways of purchasing, organizing, and delivering health care (Mathauer & Wittenbecher, 2013). This paper focuses on health services; price setting and regulation for goods, in particular, medicines and medical devices, follow different approaches that are detailed elsewhere (WHO, 2015).

Provider payment systems consist of one or more payment methods including prices and rules, regulations, and supporting systems such as contracting and monitoring mechanisms. These systems create economic signals and incentives that influence behavior. Any payment method has three dimensions: the base upon which prices are defined and set; the process by which the price level is determined; and the price level per unit of payment (Reinhardt, 2006, 2011, 2012). This paper focuses on the second and third dimensions and describes the processes by which price levels are determined.

Price setting refers to an administrative process or negotiation by which prices are determined after the unit for payment is established (e.g., a general practitioner service, a day of care in a residential facility, or a case of hospitalization). These processes can be grouped into three main methods (Reinhardt, 2012):

- Individual negotiations between providers and purchasers.
- Collective negotiation between associations of providers and purchasers.
- Unilateral decisions by purchasers.

From a societal perspective, the price is the amount that must be paid to elicit the supply and quality of health care services that society wishes to have and is willing to pay for. Hence pricing supports broader health systems objectives, i.e., guarantee coverage and financial protection, enhance access and quality, and increase efficiency.

Price regulations usually aim at ensuring price transparency, setting price ceilings on commercial health plans, defining rules for out-of-network provider prices, and instructing providers on conditions of billing within the legislative framework for the health care sector. This paper focuses on balance billing in which providers are permitted to charge patients more than the price established for covered services, and limitations imposed on balance billing that have been established in some settings as a means of financial protection.

---

1 A set of prices and rules used by a purchaser to pay a provider may also be referred to as “tariff”.

2 This legislative framework usually comprises a competition, consumer and market authority.
Middle-income countries represent more than 70% of the world’s population and a large share of the disease burden (World Bank, 2019). While increases in public spending on health are occurring across all countries, the share of public spending on health doubled between 2000 and 2016 in middle-income countries (WHO, 2018). With the increase in public spending on health, countries are paying more attention to value for public spending on health, and the decisions about how to channel funding and organize services to respond to people’s needs. This is particularly true for inpatient services and curative outpatient care, which accounts for 70% of total public spending on health on average globally (WHO, 2018). As health systems mature, policy decisions about the services covered, payments to providers, and the conditions for those payments become the determining factors in individual care-seeking behaviors (Getzen, 2006). Copayments can determine an individual’s decision about whether and which care to access; as such, policies about coverage, payments and prices thus support the progress towards UHC, especially in middle income countries. Given that health care is far from being a classic market for goods and services, the economic rationale for setting prices is to control costs, foster competition on quality, and mitigate against excessive financial claims (Kumar et al., 2014).

Policy interventions are particularly important because health care markets are characterized by such failures as information asymmetry and lack of information on prices and quality that preclude consumer choice. For many commodities, consumers assess the price and value of goods; in health in developed countries, users have health insurance or access to public services and, consequently, they pay nothing or a relatively small co-payment when using health services. Users are also represented in the market by agents (health care practitioners) instead of operating by themselves, and thus face information asymmetry. These differences make consumers less sensitive to price signals. In addition, the price signals that connect purchasers and providers operate differently because prices are not formed directly by the interplay of demand and supply.
Price setting and regulation for health services is a key component of strategic purchasing. It is linked with revenue raising, given that ultimately the prices must be in line with the available resources. There are also associations with pooling, i.e., price setting and regulation can be used to harmonize payment methods and rates across different schemes or pools. Countries have aligned pricing policies with the broader goals of ensuring financial protection, equitable distribution of resources according to health needs, promotion of quality and public health objectives, as well as controlling the growth in health care expenditures and increase efficiency (Table 1).

Table 1. Key health financing policy issues and ways in which countries have aligned pricing and policy goals

<table>
<thead>
<tr>
<th>Policy issues</th>
<th>Ways in which countries have aligned pricing with policy goals</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue raising</strong></td>
<td>Prices are set within the boundaries of available resources.</td>
</tr>
<tr>
<td>Ensuring that promised benefits do not exceed available revenues to avoid implicit rationing and informal payments.</td>
<td>Prices can be used to harmonize payment methods and rates across different schemes or pools, and strengthen cross subsidization across risk pools. Price differences across pools can, on the other hand, worsen the fragmentation and increase inequity across pools and their members.</td>
</tr>
<tr>
<td><strong>Pooling</strong></td>
<td>Prices are set at appropriate levels so as not to offset incentives in payment mechanisms. In example, prices for capitation payments must be at the appropriate level to avoid the provision of low quality care, provider selection of healthier patients, or referral of complex cases that require a higher intensity of services to another service provider. Similarly, fee for service payments should be priced to avoid provider incentives to increase volumes by providing additional (unnecessary) services. Balance billing (in which providers charge higher than the regulated prices) can be prohibited to promote financial protection.</td>
</tr>
<tr>
<td>Ensuring that pooling enables the equitable distribution of resources according to needs, and the provision of public health goods.</td>
<td></td>
</tr>
<tr>
<td>Policy issues</td>
<td>Ways in which countries have aligned pricing with policy goals</td>
</tr>
<tr>
<td>-----------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Purchasing</strong></td>
<td>Price adjustments are typically made to ensure coverage and access, for example, to health care providers in rural and remote areas; those treating disproportionately high numbers of low-income or high-cost patients to ensure coverage and quality; and for facilities providing medical education. Price schedules enable purchasing services from the private health care sector and provide benchmarks for negotiations between private purchasers and health care providers.</td>
</tr>
<tr>
<td><strong>Financial management</strong></td>
<td>Limits are established on total annual health spending.</td>
</tr>
</tbody>
</table>
The process by which prices are determined can be grouped into three approaches:

- Individual negotiations between providers and purchasers.
- Collective negotiation between associations of providers and purchasers.
- Unilateral decision by purchasers.

Regardless of the approach used, there is an assumption that providers have the ability to respond to financial incentives. We assume, therefore, that provider costs are not exogenous; in other words, providers exercise a degree of control over their costs and do not operate under a fixed cost structure.

4.1. INDIVIDUAL NEGOTIATIONS

Under individual negotiations, prices are agreed upon through negotiations between an individual purchaser, such as a health insurer or health coverage scheme, and an individual provider of health care services. There are several key features of individual negotiations. Like the negotiation of any good, prices reflect the parties’ respective bargaining positions. Under individual negotiations, a concentration of purchasers and providers with stronger market power will have equally strong bargaining power. In theory, if a purchaser covers a large share of the population, beneficiaries can be guided to use “in-network” providers with which it contracts. Under such a system, providers may agree to accept relatively lower prices from the purchaser to ensure patient volume and capture guaranteed revenue. However, in practice, providers with good reputations or brands, specialized services, or those representing the largest or sole provider in the region have strong leverage to demand higher prices from purchasers and can control price changes over time (Baker et al., 2014; Berenson et al., 2015).

Under individual negotiations, there will be price discrimination, in which identical services can be purchased by different purchasers at different prices. An example of individual price negotiation is the United States of America (US) private health care market, characterized by variations in prices for the same services that bear little relation to the cost of providing those services, its quality or patient severity (Commonwealth of Massachusetts, 2017). In addition, administrative costs are high because individual negotiations with multiple purchasers are associated with higher expenditures on health insurance marketing and administration, negotiation time, claims assessment and other billing activities.
4.2. COLLECTIVE NEGOTIATIONS

Under collective negotiations, a national purchasing agency or an association of purchasers (i.e., health insurers) negotiate with associations of hospitals or health providers. The outcome of these negotiations would typically be a uniform fee schedule that would apply to all purchasers and providers. Wide differences exist in the levels of negotiation. For hospital services across OECD countries, prices are established through collective negotiations at central level (e.g., Australia, France, Greece, Hungary, Japan, Korea, Austria, Belgium, and Turkey; or local level (e.g., Finland, Spain, Sweden, Canada, Switzerland). In Germany, Denmark, Italy, and Poland, diagnosis-related group (DRG) weights are centrally defined and rates are set at local level (Paris, Devaux & Wei, 2010).

There are several key features of collective negotiations. Price discrimination present in individual negotiations is eliminated, given that an identical service is purchased at the same price. Collective negotiations also face much lower administrative costs in comparison with individual negotiations, given that substantially fewer resources are dedicated negotiations with purchasers. At the same time, the level of conflict among the different stakeholder groups participating in the negotiation may increase as the space and the scope of negotiations widens. The process reflects in many cases the strength of a country’s domestic institutions and associations. Representatives of provider associations must have the mandate to negotiate – whether legal or explicitly expressed by their respective association. The degree of bargaining power of the different professional associations may result in lower prices and payment for those with weaker influence.

In addition, competition policy and legislation has bearing on the ability to engage in collective negotiations. The methods and processes may be subject to competition laws and regulations, depending on whether health price negotiation is considered an economic activity or conducted in the interest of social welfare. Competition law in the European Union recognizes that doctors and hospitals are economic entities within a market, but that public health purchasers have a social purpose (Kumar et al., 2014). Therefore price negotiations for health prices are permitted.

4.3. UNILATERAL PRICE SETTING

The third method of determining price levels is unilateral administrative price setting by a purchaser. When prices are administered, a form of yardstick competition rewards a given firm depending on its standing vis-a-vis an exogenous benchmarking independent of the costs incurred by each provider. For example, a purchaser could choose to reimburse hospitals at the average costs of production per unit of service observed across a set of providers. By doing so, this gives incentives to higher-cost providers to improve efficiency and reduce their costs. At the same time, providers with below-average costs have incentives to keep costs below the benchmark to retain the marginal difference. Where prices are set unilaterally by a purchaser, providers can compete on quality rather than price to attract consumers and increase volumes. As such, pressures to reduce costs could result in efficiency gains rather than reduced quality. Fixed price systems also allow transferring the financial risk linked to service provision from the purchaser to the provider.
Table 2. Process of price setting, advantages, disadvantages, key requirements, and country examples

<table>
<thead>
<tr>
<th>Individual negotiations between providers and purchasers</th>
<th>Advantages</th>
<th>Disadvantages</th>
<th>Institutional requirements</th>
<th>Country examples for hospital services</th>
</tr>
</thead>
<tbody>
<tr>
<td>In theory, purchasers can accept lower prices from designated providers to ensure patient volume and capture guaranteed revenue.</td>
<td>Providers with good reputations, specialized services, or sole providers can negotiate higher prices and control price changes.</td>
<td>High administrative capacities and expenditures for marketing, billing, and claims assessment.</td>
<td>US private insurers, private for-profit hospitals in Thailand and Mexico, specialist services in South Africa.</td>
<td></td>
</tr>
<tr>
<td>May allow more flexibility in adapting services to patient’s preferences.</td>
<td>Price discrimination exists in which different payers pay different prices for the same services.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>No price transparency exists.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Administrative costs can be high because of expenditures on health insurance marketing and administration, negotiation time, and billing activities linked to multiple purchasers.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Requires strong health information systems and human resource capacities.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Where cost-based, requires reliable detailed cost data from providers.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Institutionalized transparent and formalized process required for negotiations.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Organized professional associations with capacity and mandate to negotiate.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Collective negotiations between associations of providers and purchasers</td>
<td>Price discrimination is eliminated, given that an identical service is purchased at the same price.</td>
<td>Price levels may reflect differing bargaining power among professional associations.</td>
<td>For hospital services, collective negotiations at central level undertaken in Australia, France, Greece, Hungary, Japan, Korea, Austria, Belgium, and Turkey; or local level in Finland, Spain, Sweden, Canada, Switzerland. In Germany, Denmark, Italy, and Poland, DRG weights are centrally defined and rates are set at local level.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Strong ability to use prices as policy instruments for public health objectives.</td>
<td>Potential for conflict among the different stakeholder groups participating in negotiations.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Allows purchasers to exert market power and reflect the overall budget and fiscal affordability of the health sector and thus limit price increases.</td>
<td>Methods and processes may be subject to competition policy and legislation, and limit application to private health care sector.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Relatively lower administrative costs in comparison with individual negotiations.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prices are transparent to providers and public.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
A comparison of the three approaches is summarized in Table 2. Like collective negotiations, the unilateral administrative method eliminates price discrimination, given that a fixed price is established. In comparison with individual negotiations, unilateral administrative price setting incurs lower administrative costs by insurers and health systems, but additional regulatory expenses may apply (Anderson & Herring, 2014). Moreover, system investments are needed to ensure that the process under unilateral price setting is transparent and promotes trust and confidence in the results.

In terms of controlling price levels, the process of collective negotiations allows purchasers to exert market power vis-à-vis providers and their groups, reflect the overall budget and fiscal affordability.
of the health sector, and thus limit price increases. They also usually impose some overall expenditure controls (i.e., volume controls). This ability is even stronger in case of unilateral administrative price setting. Evidence (primarily from the US) suggests that, where properly structured and evaluated, unilateral price setting by a purchaser performed better in reducing cost growth in comparison with market-based systems (Anderson, 1991, Atkinson, 2009; Sommers, White & Ginsburg, 2012; Murray & Berenson, 2015, Anderson et al., 2019).

From an international perspective, the comparative price level index for hospital services is lower in France where 83% of revenues are based on negotiated prices set within an overall budget envelope as compared with the US (Lorenzoni & Koechlin, 2017). In the hospital sector, evidence is mixed as to whether competition for quality is more likely to occur in markets with fixed prices (Allen, Fichera & Sutton, 2016; Anderson, 1991; Gaynor, Moreno-Serra & Propper, 2013; Gaynor & Town, 2011).

### 4.4. PRICE ADJUSTMENTS AND ADD ON PAYMENTS TO INCORPORATE PROVIDERS’ EXOGENOUS DIFFERENCES IN COSTS

Price adjustments and add-on payments are common when prices are set unilaterally or negotiated collectively, to ensure that specific services or caring for specific populations are covered, particularly where there are additional costs of providing care or it is considered unprofitable. In this manner, pricing can be an important tool in allocating resources to where they are most needed.

**Table 3. Price adjustments and add on payments to incorporate providers’ exogenous differences in costs**

<table>
<thead>
<tr>
<th>Country</th>
<th>Geographic adjustments</th>
<th>Outlier payments</th>
<th>Public health goods</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia</td>
<td>Adjustments made for approximately 400 hospitals serving small, rural or remote populations, based on size, location and type of services.</td>
<td>Adjustments are made for outliers, with long-stays receiving a per diem rate.</td>
<td>For population based services that are not described in terms of activity, block funding is directed to states and territories to allocate to the hospitals.</td>
</tr>
<tr>
<td>England</td>
<td>Costs are multiplied by nationally determined by a market forces factor (MFF), which is unique to each provider and reflects relative costs of care across the country, with London providers attracting the largest MFF.</td>
<td>Adjustments are made for long or short stays and specialized services.</td>
<td>Adjustments are made to support specific policy goals such as providing care compliant with best practices.</td>
</tr>
<tr>
<td>Country</td>
<td>Geographic adjustments</td>
<td>Outlier payments</td>
<td>Public health goods</td>
</tr>
<tr>
<td>-------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>France</td>
<td>Geographic adjustment is made only for Parisian area (Ile-de-France) and for overseas territories.</td>
<td>Adjustments are made both for long and very short stays and specialized services.</td>
<td>Add-on payments are made for medical education, research, investments for improving quality of care and for supporting local public policy goals such as providing prevention, out-reach for precarious populations, etc.</td>
</tr>
<tr>
<td>Germany</td>
<td>Recently, the government has initiated add-on payments to hospitals if they are located in financially unattractive regions, but are vital to medical services to the region.</td>
<td>Since 2018, 205 add-on payments were made for patients with high needs for nursing care or the provision of additional services and pharmaceuticals which are not included in the DRG system yet.</td>
<td>Add-on payments are made for medical education, specialized units and medical centers or the delivery of care to medically demanding patients.</td>
</tr>
<tr>
<td>Japan</td>
<td>None.</td>
<td>Adjustments are made for long stays.</td>
<td>None. Public health goods are funded from different sources (i.e., screening by health plans directly contracting providers, public health and immunization by direct gov’t funding and user charges).</td>
</tr>
<tr>
<td>Thailand (UCS)</td>
<td>Adjustments are made for districts having higher unit costs due to sparse population such as mountainous areas or island districts to ensures adequate funding for operations.</td>
<td>No adjustment of outliers.</td>
<td>No adjustments; such services are mostly funded by the Ministry of Public Health.</td>
</tr>
<tr>
<td>United States (Medicare)</td>
<td>Medicare Wage Index accounts for local market conditions, by adjusting national base payment rates to reflect the relative input-price level in the local market.</td>
<td>Outlier payments are added for cases that are extraordinarily costly.</td>
<td>Operating and capital payment rates are increased for facilities that operate an approved resident training program (on the basis of hospital’s teaching intensity) or that treat a disproportionate share of low-income patients.</td>
</tr>
</tbody>
</table>
Geographical price adjustments are made to ensure that health facilities are adequately reimbursed and compensated for factors outside their control. Adjustments are also made for goods that broadly benefit society and communities, such as medical education and public health activities. In some settings, prices are adjusted to account for activities related to education, research, and innovation as well as national priorities including certain categories of medical treatment (Table 3).

### 4.5. COST-BASED PRICING

Where prices are cost-based, the costs per unit of service, economies of scale and scope, high entry and capital costs and marginal benefits of quality should be factored in to pay providers a fair and equitable price. Cost-based prices should reflect the costs that a reasonably efficient provider incurs in supplying services at the quality expected by the purchaser, while at the same time recognising the legitimate and unavoidable costs faced by some providers.

To estimate costs, purchasers use different data sources and costing methodology to structure the information collection systems and verification. The process of activity and data cost collection varies widely across settings in terms of the scope of the exercise, grouping of clinical conditions, definition of costs for inclusion and exclusion, sample sizes and frequency of data collection. In Thailand, micro costing data is being used to establish actual costs (Khiaocharoen et al., 2011). In some cases, such as independent physicians’ practices in the US, the fee schedule is based on relative resources needed to provide each service because there is no dataset of costs for physicians’ practices. In other cases, such as the Republic of Korea (Korea), the availability and reliability of cost data is a key challenge as most providers are private and reluctant to provide detailed information on their financial conditions. Well-developed health information systems, human resource capacity and ready access to reliable data are prerequisites for effective use of cost-based payment systems by regulators (Özaltın & Cashin, 2014).
4.6. BALANCE BILLING AND FINANCIAL PROTECTION

Different policy approaches – ranging from allowing specialists to charge higher prices (e.g., France) to regulating the co-payments users face (e.g., Japan and Korea) – influence the level of household out-of-pocket expenditure and access to care. A key policy question is whether the prices set are binding for providers or whether the providers are permitted to charge patients more than the price set for covered services. Whether or not prices cover the full cost of a service is an important policy lever that influences the affordability of health care services to individuals (Kumar et al., 2014). Balance billing means that health care providers charge patients for amounts higher than the fixed or negotiated prices, and the patient must pay the difference. Where balance billing is not prohibited, some groups of patients may face additional out-of-pocket fees. The policy of fully reimbursing prices set influences the affordability of health care services to individuals. In the US, for example, it is common that balance billing occurs when patients are billed for services provided by providers outside of their insurance network (Lucia et al., 2017). In some settings (e.g., Japan, Malaysia, Republic of Korea, Thailand, Germany, and the USA Medicare program for participating providers), balance billing is prohibited to increase affordability and ensure financial protection.

4.7. USING PRICE LEVELS TO CONTROL FOR VOLUMES AND AIM FOR BUDGET NEUTRALITY

Prices are also influenced by the budget envelope. Expenditure ceilings have been used to link prices to the overall budget and redistribute resources for health among various providers. In some settings, overall growth in health care spending is constrained by using macro-economic metrics, e.g., economic growth rates, expected payroll increases, inflation rates, increases in health care utilization, and population growth and ageing (Reinhardt, 2012).

For example, in France, for high volume and fast-growing DRGs (i.e., knee prosthesis and cataract surgery), the Ministry sets a threshold based on the growth rate for that activity nationally. If the hospital’s caseload grows faster than the threshold, the price is reduced by 20% (Or & GandréI, 2019).

In Germany, a hospital’s budget is linked to changes in the volume of services thereby limiting strong fluctuations in the overall budget from year to year. Deductions are used to incentivize hospitals to remain within the negotiated budget. If a hospital performs more services than agreed upon, it receives only 35% of the reimbursement rate; if a hospital performs fewer services than negotiated, it receives a reimbursement of 20% for the services it should have theoretically performed (Schreyögg & Milstein 2019).

In Japan, the Prime Minister establishes the global revision rate, or the de facto global budget for health expenditures based on an evaluation of the political and economic situation. Factors considered
include information from the survey of pharmaceutical prices and data about the revenues and expenditures in health care facilities. Subsequently a line-by-line revision of the fee schedule is undertaken based on the global budget constraint and changes in volume and prices. The government contains expenditure increases by lowering the fees for items that have had rapid increases in volume and/or can be delivered at lower costs by providers. For example, physician fees for an initial visit are four-times higher than for a repeat visit (Ikegami, 2019).

4.8. INSTITUTIONAL ENTITIES FOR PRICE SETTING AND REGULATION

In recognition of its complexity, many countries have established or designated specific entities to carry out price setting and regulation (Barber, Lorenzoni & Ong, 2019b). In some settings (e.g., England, Japan, Republic of Korea, Thailand), the tasks for price setting and regulation have been under the responsibilities of the relevant government ministry. The benefits of this approach are strong linkages among the different levels of care and the close alignment between pricing policies and government objectives.

In other settings, independent agencies were established with the responsibility for developing and updating hospital prices and fee schedules. This has occurred in Australia, France, Germany, and the state of Maryland in the US, for example. The mandate of these agencies is to develop a credible price schedule for hospitals, including grouping services based on their complexity, taking into consideration the available health resources, burden of disease, and clinical protocols and pathways.

Characteristics of successful systems include political independence, formal systems of communication with stakeholders, credibility in the eyes of the public, freedom from conflicts of interest, and political standing to resist both industry capture and political pressures. In some cases, such as Germany, these entities have independent sources of funding that are separate from general revenues.

A balance must be found between maintaining dialogue with stakeholders, including the health industry, while also observing objectivity and independence. To address this challenge, formal consultation processes have been implemented that involve stakeholders in the discussion of the base price and the cost elements that it covers. Feedback from health care providers involved in care provision may ensure acceptability of the regulated prices.
Experiences in price setting and regulation in middle- and high-income settings provide lessons learned relevant for all countries in their strategic purchasing. The main objective of pricing in the context of strategic purchasing is to change provider behavior. Price setting may be particularly relevant for low- and middle-income settings that are increasing their public funding to health and looking to other settings for useful experiences. In this paper, we introduce the approaches to price setting in different countries, and how countries have used prices to send signals to health care providers and align their behaviors with policy objectives, such as coverage and financial protection.

Among the three approaches to price setting, both collective negotiations and unilateral price setting have several key advantages, including eliminating price discrimination. Countries have used both approaches as policy levers to drive provider behaviors and promote fiscal affordability. Under both approaches, price adjustments can be made to provide additional resources for health facilities that serve low-income individuals and communities, thereby ensuring a more equitable distribution of health resources and better coverage. Transparency is higher in such systems.

Many countries have shifted towards cost-based pricing. Where prices are cost-based (average or marginal) or normative (efficient), both collective negotiation and unilateral price setting require information about input costs, output volumes, and outcomes. This usually implies investments in health information systems, human resource capacity for data collection and analysis, and ready access to reliable data. In several settings, reforms have been implemented alongside investments in data collection and analysis needed to monitor progress. Where prices are not cost-based, evidence is needed to justify prices as fair. As such, low- and middle-income settings can initiate payment reforms and, in doing so, build critical capacities in health information systems and data collection.

Both collective negotiations and unilateral price setting require institutionalized, accountable and transparent processes for setting prices or negotiating them. This requires clear understanding among providers and purchasers about the rules and processes for price setting, and that such processes are done in a transparent, equitable and fair manner within the legislative framework for the health care sector.

In several settings, specialized entities have been established to separate the technical task of determining costs from the more political exercise of negotiating how much to pay for services. In some cases, data are commissioned or collected to estimate the cost of providing services upon which prices are then based. Characteristics of such systems include political independence, formal systems of communication with stakeholders, and freedom from conflicts of interests, and flexibility to adjust prices in response to both provider behaviors and external factors such as changes in market structure, and legitimate and unavoidable costs faced by some providers.

Ultimately, pricing is not only about covering costs but also providing the right incentives. Countries should fully use pricing as another key instrument to drive broader health system objectives.
REFERENCES


Murray R, Berenson RA. Hospital Rate Setting Revisited. Dumb Price Fixing or a Smart Solution to Provider Pricing Power and Delivery Reform? The Urban Institute; 2015.


For additional information, please contact:

Department of Health Systems Governance and Financing
Universal Health Coverage (UHC) across the Life Course Division
World Health Organization
20, Avenue Appia
1211 Geneva 27
Switzerland

Email: healthfinancing@who.int
Website: https://www.who.int/health-topics/health-financing